Zhitong Finance App News, Shengnuo Biotech (688117.SH) announced that Meishan Huilong Pharmaceutical Technology Co., Ltd. (“Meishan Huilong”), a wholly-owned subsidiary of the company, recently received the “Certificate of Export of APIs from the Sichuan Drug Administration of the People's Republic of China” from the Sichuan Drug Administration to export to the European Union: tirzepatide (Tirzepatide).

This time, the titerpopeptide API production line produced by Meishan Huilong, a wholly-owned subsidiary of the company, successfully passed the on-site inspection by the Sichuan Drug Administration and successfully obtained the “Certificate of API Export to the EU”, indicating that the production quality management system of the company's wholly-owned subsidiary Meishan Huilong complies with China's GMP requirements, and is equivalent to meeting the European Union, World Health Organization and ICHQ7 drug GMP standards. Obtaining the above certification is a high recognition of the company's R&D capabilities, production process and management level. It provides key entry qualifications for the company's products to enter the EU market, helps the company expand its API business in the global market, enhances the company's competitiveness in the international market, and has positive significance for the company's long-term operation and steady development.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.